




Solagran Limited
ACN 002 592 396
Level 1
480 St Kilda Road
Melbourne, 3004
Victoria
Australia
T 61 3 9820 2699
F 61 3 9820 3155
W www.solagran.com

Solagran Limited – Market Update

July 2010



Disclaimer

Where this presentation contains “forward-looking statements”, these statements are based on information and assumptions and involve expectations or beliefs as to future events or results as understood at the date of this presentation. All forward-looking statements are represented in good faith and have a reasonable basis at the time that they are made. However, such statements are subject to various risks and uncertainties, many of which are beyond the control of the company, which could cause actual results to differ materially from those represented by the forward-looking statements.

Any representation in this presentation should not be relied upon as to its accuracy or completeness nor as a recommendation or forecast by Solagran or its advisors. Solagran advises that Independent financial advice be sought before concluding any binding decision made in connection with this presentation.


This presentation does not purport to contain all the information that may be required to evaluate an investment in Solagran and, in particular, may not contain all such information as would reasonably be required and reasonably expected for the purpose of making an informed assessment of:

- _ the rights attaching to the shares; and
- _ the assets and liabilities, financial position, profits and losses and prospects of Solagran;
- _ the merits of subscribing for or purchasing shares in Solagran and the risks involved in such an investment.

The representations made within this presentation should not be construed as either an offer to buy or sell any securities of Solagran in any jurisdiction.


Solagran and its related bodies corporate, its officers, employees and advisors expressly disclaim all responsibility relating to or resulting from the use of the material and information contained in this presentation and exclude all liability whatsoever (including negligence) for any loss or damage suffered by any person as a result of the use of any of the information in this presentation or any error or omission there from. Subject to any continuing obligations under applicable law and the Listing Rules of ASX Limited, Solagran does not undertake any obligation to publicly update or revise any of the forward looking statements in this presentation or any changes in events, conditions or circumstances on which any such statement is based.

Presentation Contents



1. Key achievements Financial Year 2009/10	4
2. Russian Visit May/June 2010	6
3. Symposia	8
4. Ropren Sales – Initial Achievements	9
5. Significant events during Russian visit	10
6. Siberian State Medical University Agreement	12
7. Production Facilities Russia	13
8. Corporate Structure	14
9. Pine Pure Range – Indonesia	17
10. Cosmetics	19
11. Bioeffective A	20
12. Investment Highlights	21
13. Appendix – Publications & Presentations	23

Key Achievements – FY 2010



- Launched world's first polyprenol drug, Ropren, as a hepatoprotector in Russia
 - Positioned as a premium product given unique properties of efficacy, mechanism of action and lack of side effects
 - Represents culmination of over 25 years research and trials since first discovery
 - Maintained clinical leadership completing numerous trials, publications and presentations
 - Well positioned to be the leading premium brand in Russia within 2 years
 - Multi-billion dollar market globally for treatment of liver disease

- Advanced clinical trials to expand application to other significant markets, including neurological conditions (Alzheimer's)

- Granted an additional 5 international patent applications

- Formalised relationship with independent distributor, Biofar, to focus solely on distributing Ropren in the Russian market


- Expanded OTC business in Australia with launch of Siberian Red (Bioeffective I) and successful listing of Bioeffective A Gel with TGA (initial production order placed with the contract manufacturer)

Key Achievements – FY 2010 (cont'd)



- o Created the Pine Pure brand of OTC products for the Indonesian mass market
- o Improved manufacturing process to increase yield of Bioeffective R substance from intermediate product by over 100%. Current manufacturing capacity up to 30kg per month.
- o Commenced design on proposed 250kg per month facility in Tomsk Special Economic Zone
- o Strengthened financial position with the introduction of the Salim Group as a strategic partner and major shareholder


Russian visit – May/June 2010




- o Solagran's Executive Chairman, Dr Vagif Soultanov, and Chief Financial Officer, David Croll, visited Russia in May and June 2010.

- o The main aims of the visit were to:
 - participate in symposia and conferences,
 - gain a better understanding of the progress being made in relation to Ropren sales in Russia,
 - meet leading specialists in Russia not already covered whose opinions are highly regarded, and
 - align, from a corporate structuring and reporting point of view, the Australian and Russian operations of Solagran.

- o Dr Soultanov with his colleagues participated in symposia held by the Pasteur Institute in St Petersburg and a Gastroenterology symposium held in the same city.



- o Under the umbrella of the Pasteur Institute, we conducted a satellite symposium solely focusing on the vast amount of scientific data which Solagran has obtained over the last two years from pre-clinical and clinical trials using Ropen.
- o Participation in these symposia led to increased awareness of Ropen in the medical community and enabled Solagran representatives to meet with leading specialists in the areas of gastroenterology, hepatology, hematology and other related areas.
- o It gave the Chairman the opportunity to discuss future plans for distribution of Ropen on the Russian market including outpatient clinics, hospitals and pharmacies throughout Russia, the former Soviet Republics and Europe.
- o In the meantime it also provided the opportunity to discuss future trials for all Bioeffectives which will help expand their applications.



International Symposia


- Pasteur Institute – International Conference “(Development) Progress in Scientific Research and Supervision of Infectious Diseases”, 18 – 20 May 2010, St Petersburg
- St Petersburg – GASTRO 2010, Scientific Medical Forum, 19 – 21 May 2010
- 2nd Conference of the Russian Psychoneuroendocrinology Association, 30 May – 1 June 2010, Moscow (sponsored by Solagran)
- 5th International Conference “Biological Foundations of Individual Sensitivity to Psychotropics” State Foundation Institute of Pharmacology Russian Academy of Medical Sciences and Administration of Presidential Affairs of the Russian Federation. “Klyazma” Moscow 1-4 June 2010

Russian Symposia

- 4th Russian Interdisciplinary Congress: “Man and problems of dependency – interdisciplinary aspects”, 26 – 29 April 2010 Arkhangelsk
- St Petersburg Medical Academy of Postgraduate Studies, 125 Anniversary Conference of Young Scientists

Upcoming Symposia discussing Ropren


WorldPharma 2010	16 th World Conference of Basic and Clinical Pharmacology 17-23 July 2010 Copenhagen, Denmark
Congress ECNP	European College of Neuropsychopharmacology Amsterdam, Holland 28 Aug to 1 Sep 2010



Ropren Sales – Initial Achievements

- Solagran launched Ropren on the Russian market at the end of February 2010.
- All sales ultimately fall under the medical direction of Solagran representative, Dr Vladimir Trusov based in Tomsk, Siberia.
- Solagran has retained to assist with the promotion of Ropren medical consultants based in St Petersburg namely Professor E. Lapteva and a leading gastroenterologist in Moscow, E. Golovanova DSc Med Science .
- Targeting multiple distribution channels (Hospitals, Pharmacies & Clinics)
- Ropren was included in the “Register list of pharmaceuticals in rendering medical aid in hospitals and other medical institutions” in the Tomsk region (June 2010)
- To date 14 hospitals from St Petersburg, Moscow, Tomsk, Novosibirsk and Kemerovo Oblast have placed orders for Ropren
- Finalising negotiations with Imperia Pharma in St Petersburg for wide scale distribution of the product in St Petersburg and surrounding regions. Imperia Pharma are the largest distributor of pharmaceutical products in St Petersburg.
- Met with country’s leading gastroenterologists, hepatologists, neurologists and neuroendocrinologists to increase product awareness and support additional trials each targeting a specific condition
- 1,200 bottles of Ropren have been sold in Russia to 10 June 2010.


Goal: Convert increased product awareness among influential specialists and the wider medical community into significant sales and a leadership position in Russia



Significant events during the Russian visit

- Meeting with renowned Russian gastroenterologist, Academician V Ivashkin.
 - Agreed to conduct specifically designed double blind, randomised, placebo controlled multi-centre clinical trials under his supervision to help understand the real mechanism of action of Ropren and its efficacy upon the liver.
- Meeting with Professor O. Minushkin, Chief Gastroenterologist, Administrative Department of the President Russian Federation.
 - Agreed to conduct small scale trials using Ropren to confirm the efficacy of the product in treating cirrhosis of the liver induced by alcoholism.
- Meeting with Dr E. Golovanova from the Central Scientific Research Institute of Gastroenterology headed by Professor L. Lazebnik from the Moscow Department of Healthcare.
 - Institute is purchasing Ropren and is to conduct further trials on 30 people suffering from steatohepatosis.


Focus on key influence leaders whose opinions are highly regarded internationally



Significant events during the Russian visit (cont'd)


- o Meeting with Dr Med Sci E Schastniy, Head of Affective States Department, Tomsk Scientific Centre, Institute of Mental Health who conducted his own trials with patients suffering mild forms of depression. According to his preliminary observations for the last 4 months, Ropren is efficacious, fast acting and importantly lacking in side effects compared to existing anti-depressant medications.
 - Solagran is starting to make arrangements to conduct multi-centre trials in this area.
- o Meeting with the Head Gastroenterologist of St Petersburg, Professor E Tkachenko Professor Tkachenko was Vice Chancellor of Mechnikov Medical Academy and Vice President of the Scientific Society of Gastroenterologists of Russia.
 - He was impressed with our achievements to date and agreed to promote Ropren to the Russian medical community and welcomed scientific publications in different reputable medical journals.
 - Professor E. Tkachenko co-chaired the session called “Ropren – New Russian Hepatoprotector of Plant Origin” at the Gastro 2010 symposium with Dr Sulttanov 20 May 2010.

Siberian State Medical University Agreement



- o During his visit to Russia, Dr Soultanov signed an agreement with one of Russia's leading medical universities, Siberian State Medical University in Tomsk providing for cooperation in:
 - Scientific, education and preparation of higher standard medical specialists for our needs
 - Conducting pre-clinical and clinical trials
 - Further research and development on theoretical and practical areas of medical applications of Solagran's Bioeffectives.


- o Solagran will work in collaboration with the University and under the agreement will have priority access to all specialists.



Production Facilities Russia

- o Planned modifications to SibEX production facility will enable us to increase monthly production capacity of Bioeffective R (substance) pharmaceutical grade to 50kg by March 2011.
- o The Tomsk Production facility currently has the capacity to produce up to 30kg of high grade pharmaceutical substance on a monthly basis.
- o Design work has commenced on the new production facility to be built in the Tomsk Special Economic Zone. This facility will have the capacity to produce a minimum of 250kg of pharmaceutical grade substance per month.
- o Solagran is currently assessing the feasibility of building an adjoining facility to the existing Tomsk plant to produce Bioeffective A and other Bioeffectives.

Corporate Structure




- o All activities in Russia will be consolidated under Solagran Son LLC .
 - This includes ownership of SibEX LLC and Solagift LLC , the entity holding the land entitlement in the Tomsk Special Economic Zone.

- o A new board of directors has been appointed with responsibility for the Russian operations.

- o Solagran and SibEX LLC's interests have been aligned with the proposed purchase of the remaining 15% in SibEX LLC. Upon finalisation of all documentation in relation to the acquisition of the minority interest, a separate announcement will be made to the market.


- o Mr Alexander Kurganov has been appointed Managing Director of Solagran Son LLC. He remains a board member of the parent company, Solagran Limited and is one of the directors of Solagran Netherlands NV.

Corporate Structure (cont'd)




SOLAGRAN SON LLC – BOARD OF DIRECTORS		
<p>Mr. Alexander Kurganov D.O.B. 20 Nov 1964</p>	<p>Managing Director</p>	<p>1987 Graduated with honours from the Tomsk Polytechnical University specialising in thermal power stations and was awarded the Lenin scholarship. From 1987-1994 Mr Kurganov worked as a research scientist for the Department of Construction of boilers-reactors while completing post graduate studies.</p> <p>From 1994 to 2006 he managed a commercial company whose activities included construction, wood processing, animal husbandry, biotechnology, agriculture and product distribution.</p> <p>Given his multi-faceted skill base over a diverse range of industries, he was appointed as General Director of SibEX LLC in 2006. As part of this role, he managed the construction of the world's first manufacturing facilities for polyprenols on an industrial scale.</p> <p>Mr Kurganov has published over 20 scientific articles and holds 2 patents.</p> <p>He was appointed to the board of Solagran Limited in 2009.</p>
<p>Professor Victor Roschin D.O.B. 30 Jan 1945</p>	<p>Head of Research & Development</p>	<p>Graduated from the Forest Technical Academy in St Petersburg and completed a PhD in Chemistry in 1981. From 1978 to 1991 he was a group leader at a Government Research Laboratory for use of the live elements of trees and worked as an associate professor at the Department of Forestry of Chemistry Production.</p> <p>From 1993-1994 he worked in China at the Nanjing Forest University where he was awarded the title of Honorary Professor. In 1995 he obtained a DSc of Chemical Sciences. Since 1998 he has been the Head of the Department of Wood Chemistry and Physical and Colloid Chemistry at the Forest Technical Academy in St Petersburg.</p> <p>Based on works by Solodky F.T. and continued by Professor Roschin, manufacturing facilities for processing of green verdure were built in Voskresensk, Sosnovo and Tver. In 2002 he was awarded a medal by the Academy of Science (Karpitsa Medal) for discovery of previously unknown scientific natural compounds. In 2003, he was awarded the title of Honoured Specialist of the Higher Education and in 2004 awarded the title of honoured specialist of the Forestry Industry.</p> <p>In 2007, based on the technology developed by Professor Roschin, the world's first production facility for manufacturing polyprenols was built in Tomsk, Siberia.</p> <p>Professor Roschin has published 327 articles and has been granted 43 patents.</p>

Corporate Structure (cont'd)




SOLAGRAN SON LLC – BOARD OF DIRECTORS

<p>Dr Vladimir Trusov</p> <p>D.O.B. 20 Feb 1960</p>	<p>Head of Medical Department</p>	<p>1983 Graduated from the Tomsk Medical University.</p> <p>Dr Trusov has 27 years of experience in psychiatry at the Central Hospital for the Tula region, the Scientific Research Institute at the Russian Academy of Medical Science and the Centre for Medical-Social Assistance. From 2002 he managed his own private medical clinic with a psychiatric department.</p>
<p>Ms Natalya Arshavskaya</p> <p>D.O.B. 27 Mar 1970</p>	<p>Head of Marketing</p>	<p>1990 Graduated from Teachers Training College and worked in a primary school. In 2004 she graduated from the Tomsk State University specialising in marketing.</p> <p>Between 1999 and 2006 she worked in advertising and marketing for a beverages company where she launched many new brands into the Russian market. She joined SibEX as a vice director in 2006 and under her management has developed trademarks such as SibEX, Forest Line, Pine Pure and VEGETEX.</p> <p>SibEX products are represented in 16 Russian cities and received an award “100 best Russian products” and also a gold medal in the international competition “Quality of products and services , Eurasia 2009”</p>
<p>Mr Arif Djafarov</p> <p>D.O.B. 26 Jul 1959</p>	<p>Independent Engineering Expert & Solagran Representative</p>	<p>1979 completed a bachelor degree in organic synthesis and in 1992 graduated from the Forest Technical Academy in St Petersburg as an engineer/technologist.</p> <p>From 1992 to 2003 he worked on a variety of chemical and mechanical technology plants associated with the forestry industry. From 2003-2007 he was Director of a construction company based in Nadym, Siberia. He joined SibEX as Solagran's representative in 2007.</p>
<p>Mr. Vladimir Podkartov</p> <p>D.O.B. 19 Sep 1953</p>	<p>Vice Director of Business Development and Communication and Company Secretary to the Board of Solagran Son</p>	<p>1976 Graduated from the Tomsk Polytechnical University as an engineer/physicist and was awarded his PhD in Physics in 1981. From 1976 to 1986 he worked in the Institute of Nuclear Physics at the Tomsk Polytechnical University. From 1987 onwards he worked in the Tomsk Municipal Administration as Deputy of the Mayor. As a Director of the Department for Social Policy he managed such areas as medicine, education and science. He is a member of the editorial board of the “Siberian Medical Journal”. He led project management teams at the Tomsk Scientific Centre of the Russian Academy of Medical Science and coordinated activities of Centres for Cardiology, Oncology and Mental Health.</p> <p>He managed the establishment of the Special Economic Zone in the Tomsk region and joined Solagran Son as an Executive Director in 2009. He has had professional training in England, Germany, France and the United States.</p>




- o Initial range of 11 OTC products (over-the-counter) progressing through the trial and registration process in Russia. Products consist of drinks, nutritional food and confectionery.
- o To date, 6 products have gained registration and approval for the remaining 5 products is expected within the next few months.
- o Solagran continues to progress arrangements relating to the launch of Pine Pure in Indonesia which is now expected to occur in the second half of FY 2011.

Pine Pure - Indonesia




Subject to receiving timely product approvals by Russian and subsequently Indonesian regulators, Solagran expects to be able to launch the Pine Pure brand of products in Indonesia in 2H FY 2011

	Q1 FY'10	Q2 FY'10	Q3 FY'10	Q4 FY'10	Q1 FY'11	Q2 FY'11	Q3 FY'11	Q4 FY'11
Concept developed								
Identified contract manufacturing & design partner								
Developed product range (bioactive additives, drinks, candies)								
Developed product formulations (15 formulae)								
Sample production (tasting, testing, select optimal products)								
Production cost evaluation								
Product design development								
Research/trials of products biological activity								
Applying for registration of products in Russia								
Receive registration approvals in Russia								
Complete packaging design & translation								
Produce product samples & documents for Indonesia								
Receive registration approvals in Indonesia								
Confirm supply & distribution agreements with Salim								
Prepare marketing program for OTC products								
Finalize contract manufacturers & costings								
Place orders for product								
Product supply to Indonesia								



- o Solagran was recently approached by a major European manufacturer of cosmetics to develop a range of products containing Bioeffectives as active ingredients.
- o Solagran representatives visited the manufacturer on their recent trip and began discussions to develop a skin care range containing Bioeffectives which would in turn be presented to their clients being most, if not all of the major cosmetic brands in the world.
- o Though discussions are in their early phase, the manufacturer expressed a great deal of interest in developing a range using Bioeffectives due to the products natural basis and unique medical qualities.
- o Solagran will work in collaboration with the manufacturer to develop formulations over the coming months.



Bioeffective A

- o Bioeffective A sales continue to gain momentum in Australia. Exclusive rights to distribution of the product expired in December 2009 allowing Solagran greater flexibility in managing the overall sales and distribution process.
- o Following an extended negotiation period, the first order for Bioeffective A for the Malaysian market was placed by our appointed distributor Nuvanta. Our contract manufacturer, Catalent, are producing Bioeffective A 160 mg capsules specifically tailored for the Malaysian market.
- o Bioeffective A's registration in Russia as a BANA (biologically active nutritional additive) will be finalised this month.
- o Following completion of the first phase clinical trial, the final submission will be made to the Food and Drug Administration in the USA to register Bioeffective A as a NDI (New Dietary Ingredient) on 6 July 2010. Solagran anticipates approval of the substance this year.
- o Solagran listed a burns gel with the Therapeutic Goods Administration in Australia in 2010. An initial order has been placed with our contract manufacturer and is now anticipated to be received this month.
- o Solagran is well advanced in the process to register the product in the United Arab Emirates. A local distributor has been identified and is ready to commence distribution of the product upon approval.


Investment Highlights



- ✓ Leading pharmaceutical group in the world in the development of polyprenol technology and applications and, more broadly, therapeutic products from Northern Hemisphere conifer species of trees
 - Bioeffectives are the result of 75 year research program and more than 5 million DSc / PhD man hours
 - 24 Patents covering production process and product applications
 - Transitioning from a scientific research phase to commercialisation phase of its discoveries

- ✓ Ropren is the first commercial polyprenol drug approved as a pharmaceutical in the world.
 - Ropren is a natural product approved as a hepatoprotector pharmaceutical product in Russia.
 - Based on its unique characteristics including efficacy, mechanism of action and undiscovered side effects, Ropren should become a leading premium drug in the multi billion \$ global hepatoprotector market.

- ✓ Ropren and polyprenols more broadly have multiple therapeutic applications and Solagran is developing products in a number of not less significant categories including neurological disorders (Alzheimer's /different forms of depression and others)




Investment Highlights (cont'd)

- ✓ Broad scientific portfolio
 - Over 10 Bioeffectives in various stages of development
 - Available for registration as either ethical, OTC or personal care products

- ✓ Launching Pine Pure as an affordable every day health brand for the mass market


- ✓ Leading manufacturing technology in extraction of Bioeffectives and, more specifically, Polyprenols

- ✓ Strong & committed management team and highly educated and experienced employees
 - Leading scientists, biochemists, organic chemists, engineers with numerous senior employees having between 20-40 years experience in the field with a significant collection of patents/research to their credit
 - Key individuals interests tied to company's success with significant share ownership either directly or through vesting shares based on achieving share price targets



APPENDIX

Recent Articles Presented and Published




Scientific conference "Current issues of clinical and experimental medicine – 2010"; 22 April 2010.
10th anniversary applied science conference for young scientists and specialists, celebrating 125 years since establishment of the Academy (MAPS)

	Monakhova I.A., Soultanov V.S., Agishev V.G.	Study of Therapeutic Properties of Ropren in Treatment of Alzheimer's Type Dementia; Poster presentation. Presenter: Monakhova I.A., psychiatrist

Congress "Man and addiction problems: Interdisciplinary aspects", Arkhangelsk, 26-29 April 2010

1.	Soultanov V.S., Roschin V.I., Agishev V.G., Kulikov A.P., Monakhova I.A., Mokhovokova I.A., Nikitina T.V.	Results of administration of new therapeutic drug Ropren to chronic alcoholics Oral presentation on the same topic. Presenter: Head physician of No.3 Skvortsova-Stepanova Psychiatric Hospital, Agishev V.G
2.	Shabanov P.D., Soultanov V.S., Nikitina T.V., Roschin V.I.	Is it possible to protect the brain by taking hepatoprotectors? Oral presentation on the same topic. Presenter: Professor, PhD Med, Head of Pharmacology Department at the S.M. Kirov Medical Military Academy, Shabanov P.D. DSc Med Sciences

Publications (Theses)




International conference "Development of scientific research and management of infectious diseases", St-Petersburg – 18-20 May 2010.

Satellite symposium on: "Potential for use of plant origin polyphenols and based on them drugs in various areas of medicine"

1.	Golovanova E.V. DSc Med Sciences , Head of gastroenterological dept at the Institute of Gastroenterology, Moscow	Treatment of Patients With Non-Alcoholic steatohepatitis with the new hepatoprotector Ropren
2.	Lapteva E.N., DSc Medical Sciences, MAPS, Managing Director of Lenmedcentre, St-Petersburg	Use of Ropren in patients with chronic viral hepatitis.
3.	Mokhovikova I.S. DSc Med Sci ., functional diagnostics, Skvortsova-Stepanova Psychiatric hospital No.3 St-Petersburg	Ropren Improves The Functional Condition (EEG) of The Central Nervous System in Patients With Chronic Alcoholism
4.	Shabanov P.D., Professor, DSc Med, Head of Pharmacology Dept at the Medical Military Academy, St-Petersburg	A study in rats of the hepato and neuroprotective properties of polyphenols containing the therapeutic substance Ropren
5.	Zaitseva M.A., PhD Senior scientist, Institute of Toxicology, St-Petersburg	Study of pharmacological activity of Ropren using a model of cranio-cerebral trauma
6.	Buryakina A.V., PhD Biology, Head of laboratory for pharmacological studies at the St-Petersburg State Chemical-Pharmaceutical Academy	Experimental animal data obtained on a model of hyperplasia of prostate gland after treatment with Ropren.
7.	Zarubaev V.V., MSc Biology Head of laboratory of Molecular basis for chemotherapy at the Institute of Influenza of the RAMS, St-Petersburg	Influence of drugs based on polyphenols on pathogenesis and influenza infection in white mice
8.	Kozlova NS PhD Microbiology –St Petersburg State Medical Academy named after I.I. Mechnikov	Sensitivity of opportunistic pathogenic micro-organisms to Bioeffective A
9.	Kozlova NS PhD Microbiology –St Petersburg State Medical Academy named after I.I. Mechnikov	Possibility to use plant origin substance Bioeffective A for sanitation of carriers of hospital strains of micro-organism and combined therapy for hospital infections
10.	Urazova L.N. – Professor DSc Med Science - Scientific Investigative Institute of Oncology – Russian Academy of Medical Sciences (Siberian Branch- Tomsk)	Anti-tumour activity of Ropren (experimental study)


Presentations at the Pasteur Institute in St Petersburg



International conference "Development of scientific research and management of infectious diseases", St-Petersburg – 18-20 May 2010.
 Satellite symposium on: "Potential for use of plant origin polyprenols and based on them drugs in various areas of medicine"

1.	Presenter – Soultanov V.S., Honourary Doctor of Chemistry, PhD Chemistry, Executive Chairman of Solagran Limited, Australia.	Solagran presentation including company documentary
2.	Presenter – Roschin V.I., Professor, DSc Chemistry, Head of Dept of Wood Chemistry, Physical and Colloid chemistry at Forest Technical Academy St-Petersburg	Role of polyprenols in live cell.
3.	Presenter – Monakhova I.A., psychiatrist at the Skvortsova-Stepanova Psychiatric hospital No.3, St-Petersburg	Ropren Treatment Of Patients With Alcohol and Narcotic Intoxication Complicated by Chronic Infection With Hepatitis B, Hepatitis C and HIV
4.	Presenter – Buryakina A.V., PhD Biology, Head of laboratory for pharmacological studies at the St-Petersburg State Chemical-Pharmaceutical Academy	Experimental animal data obtained on a model of hyperplasia of prostate gland after treatment with Ropren.
5.	Presenter – Bespalov V.G., DSc Med, oncologist, Head of Chemoprevention and oncopharmacology laboratory at the Petrov N.N. Institute of Oncology, St-Petersburg	Potential for use of Ropren in oncology.
6.	Presenter – Shabanov P.D, DSc Med Science St Petersburg Military Medical Academy	New data concerning the pharmacodynamics of the Hepatoprotector Ropren in comparison with Heptral.
7.	Presenter Urazova L.N. Professor DSc Institute of Oncology of the Siberian Branch of RAMS, Tomsk.	Anti-tumour activity of Ropren
8.	Presenter Kozlova N.S . PhD Microbiology – St Petersburg State Medical Academy after I.I. Mechnikov	Sensitivity of opportunistic pathogenic micro-organisms to Bioeffective A and possibility to use it for sanitation of carriers of hospital strains of micro-organism and combined therapy for hospital infections.
9.	Presenter Lapteva E.N. DSc Medical Sciences, MAPS, General Director of Lenmedcentre, St Petersburg.	Use of Ropren in patients with chronic viral hepatitis.


Presentations at Gastro 2010 – St Petersburg



12th International Slavic-Baltic Scientific Forum "St. Petersburg – Gastro 2010"

1.	Professor Roschin V.I. St Petersburg Forest Technical Academy	"Ropren – stimulator of natural regeneration of the liver"
2.	Khnychenko L.K. St Petersburg Institute of Experimental Medicine of the Royal Academy of Medical Science	"Ropren's specific activity during toxic damage of the liver" (results of experimental studies)
3.	Libman A.E. MAPS St Petersburg	Morphological changes in the liver during treatment with Ropren"
4.	Lapteva E.N. St Petersburg Medical Academy of Postgraduate Studies	"Results of clinical trials of Ropren preparation"
5.	Golovanova E.V. Moscow Central Scientific Research Institute of Gastroenterology	"Ropren's efficacy in treatment of non-alcoholic steatohepatitis"
6.	Egorov D.V. Military Medical Academy of St Petersburg	"Use of Ropren in clinical practice (clinical case: patient with liver cirrhosis)"
7.	Dr Souldanov V.S. Executive Chairman Solagran Limited	Nutritional Aspects and Bioeffectives"

Recent Presentations / Publications



2 nd All-Russian conference of the Russian Association of psychoneuroendocrinologists, Moscow. 30 May to 1 June 2010		
1.	Soultanov V.S., Fedotova Yu.O., Roschin V.I., Nikitina T.V.	Evaluation of efficacy of polyprenolic preparation from Picea abies (L.) Karst and Bioeffective A for treatment of Alzheimer's type dementia in male rats.
2.	Fedotova Yu.O., Soultanov V.S., Roschin V.I., Nikitina T.V.	Effect of Bioeffective A on restoration of the balance thyroid hormones in case of estrogens deficit in female rats.
3.	Shabanov P.D., Soultanov V.S., Roschin V.I., Nikitina T.V., Lebedev A.A., Bychkov E.P., Proshin S.N.	Toxic subacute hepatosis with encephalopathy in rats: Evaluation of protective effect of Ropren.
4.	Soultanov V.S., Buryakina A.V., Frolova N.Yu., Roschin V.I., Nikitina T.V.	Effect of Ropren on animals with hyperplasia of prostate gland.
5.	Soultanov V.S., Roschin V.I., Agishev V.G., Monakhova I.A., Kulikov A.P., Nikitina T.V.	Clinical application of polyprenols from conifer needles of Picea abies (L.) Karst for patients with Alzheimer's type dementia with background vascular damage of the brain.
6.	Soultanov V.S., Roschin V.I., Rozengart E.B., Nikitina T.V.	Protective effect of polyprenols from conifer needles and Glyatilin on key neuromediator systems in different sections of the brain studies on experimental model of acute hepatic encephalopathy.
7.	Mokhovikova I.A., Soultanov V.S., Monakhova I.A., Agishev V.G., Roschin V.I., Nikitina T.V.	Study of effect of Ropren on neurophysiological conditions of the central nervous system in patients with chronic alcoholism using a method of electroencephalography.
8.	Fedotova Yu.O., Soultanov V.S., Roschin V.I., Nikitina T.V.	Evaluation of efficacy of polyprenolic preparation from Picea abies (L.) Karst and Bioeffective A for treatment of Alzheimer's type dementia in male rats.
	Oral Presentations:	
	Shabanov P.D., Professor, DSc Med	Toxic subacute hepatitis with encephalopathy in rats: Evaluation of protective effect of Ropren .

5 th International Conference " Biological Foundations of Individual Sensitivity to Psychotropics" State Foundation Institute of Pharmacology Russian Academy of Medical Sciences and Administration of Presidential Affairs of the Russian Federation. Klyazma Moscow 1-4 June 2010		
1.	Shabanov P.D. DSc Med Science - Oral Presentation	"Behavioural effects of Ropren"
2.	Fedotova Yu.O., DSc Biology	Evaluation of efficacy of polyprenols from conifer needles of abies (L.) Karst and Bioeffective A on Alzheimer's type dementia in male rats


Publications at the World Psychiatric Regional Meeting



World Psychiatric Association Regional Meeting St Petersburg
10 – 12 June 2010

1.	Monakhova I.A. Soultanov V.S. Agishev V.G	Study of the therapeutic properties of Ropren in the treatment of Alzheimer's type dementia
2.	Soultanov, V.S. Roschin V.I. Monakhova I.A. Agishev V.G	Results of the use of Ropren in treatment of chronic alcoholism

Upcoming Presentations / Publications




« WorldPharma 2010 », 16th World Conference of Basic and Clinical Pharmacology 17-23 July 2010, Copenhagen, Denmark

1.	Yulia Fedotova, Vagif Soultanov, Victor Roschin, Tamara Nikitina	Ropren is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25-35)-induced amnesia Laboratory of Neuroendocrinology, Pavlov Institute of Physiology Russian Academy of Science, Solagran Limited, Melbourne, Australia, Department of Wood Chemistry, State Forest-Technical Academy, Laboratory of Functional Biochemistry of Invertebrates, I.M. Sechenov Institute of evolutionary Physiology and Biochemistry, Russian Academy of Science. Poster presentation - Fedotova Yu.O., DSc Biology

23 Congress ECNP (European College of Neuropsychopharmacology), Amsterdam, Holland, 28.08-01.09.2010

1.	P.D.Shabanov, Soultanov V.S., Roschin V.I., Nikitina T.V., Lebedev A.A., Bychkov E.R., Proshin S.N	Defensive effects of Ropren in a rat model of subacute hepatitis with encephalopathy . Military Medical Academy, St. Solagran Limited, Melbourne, Australia, Department of Wood Chemistry, State Forest-Technical Academy, Laboratory of Functional Biochemistry of Invertebrates, I.M. Sechenov Institute of evolutionary Physiology and Biochemistry, Russian Academy of Science Stand presentation - Professor, DSc Med Science, Head of Pharmacology Department at the S.M. Kirov Medical Military Academy, Shabanov P.D.


Recent Presentations / Publications



Articles

1.	Fedotova Yu.O., Soultanov V.S., Kuznestova N.N., Roschin V.I., Nikitina T.V	<p>Effect of new polyprenols therapeutic substance Ropren on rats with anxiety-depressive behaviour caused by experimentally induced Alzheimer's disease.</p> <p>The article has been submitted to the journal: Experimental and clinical pharmacology</p>
3.	Shabanov P.D. Soultanov V.S. Lebedev A,A. Bychkov E.R. Proshin S.N.	<p>"Protective properties of polyprenols on a model of sub-acute hepatitis with encephalopathy in rats".</p> <p>Article published in the Medical Academic Journal 2010 Vol 10 No 2 page 50-57.</p>

Other Publications



1.	Bespalov V.G., Soultanov V.S., Scherbakov A.M., Novik V.I., Cheoik O.F., Kalinovsky V.P	" Stomach precancerous conditions and changes and their correction" This article was submitted and published in Medline No 2-3 2009 r
2.	Soultanov V.S., Punshon T.V.	" Nutritional Aspects and Bioeffectives" This article was published in the journal 'Clinical Nutrition"